The implications and requirements of transcatheter aortic valve replacement in low-risk patients
Transcatheter aortic valve replacement (TAVR) is a transformative technology that has changed the management of patients with severe, symptomatic aortic stenosis. The use of TAVR in intermediate- to high-risk patients has been validated in several rigorously performed, randomized clinical trials. Recent studies using newer generation devices have demonstrated the noninferiority of TAVR as compared with surgical aortic valve replacement in low-risk patients, supporting the increased utilization and expansion of TAVR. The use of TAVR in low-risk patients has important implications and requires a multifaceted approach that includes a highly functional multidisciplinary heart team for careful patient selection; a need to understand and help mitigate certain key complications, such as stroke, paravalvular regurgitation, and conduction disturbances; careful data collection for continual outcome assessment and improvement; and the necessary expertize and procedural volume to maintain excellent outcomes and ensure optimal clinical care pathways.
Errataetall: |
CommentIn: Anatol J Cardiol. 2020 Jan;23(1):1. - PMID 31911572 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
---|---|
Enthalten in: |
Anatolian journal of cardiology - 23(2020), 1 vom: 01. Jan., Seite 2-9 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tuzcu, Emin Murat [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 27.10.2020 Date Revised 27.10.2020 published: Print CommentIn: Anatol J Cardiol. 2020 Jan;23(1):1. - PMID 31911572 Citation Status MEDLINE |
---|
doi: |
10.14744/AnatolJCardiol.2019.39293 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM305109707 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM305109707 | ||
003 | DE-627 | ||
005 | 20231225120447.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.14744/AnatolJCardiol.2019.39293 |2 doi | |
028 | 5 | 2 | |a pubmed24n1017.xml |
035 | |a (DE-627)NLM305109707 | ||
035 | |a (NLM)31911564 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Tuzcu, Emin Murat |e verfasserin |4 aut | |
245 | 1 | 4 | |a The implications and requirements of transcatheter aortic valve replacement in low-risk patients |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.10.2020 | ||
500 | |a Date Revised 27.10.2020 | ||
500 | |a published: Print | ||
500 | |a CommentIn: Anatol J Cardiol. 2020 Jan;23(1):1. - PMID 31911572 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Transcatheter aortic valve replacement (TAVR) is a transformative technology that has changed the management of patients with severe, symptomatic aortic stenosis. The use of TAVR in intermediate- to high-risk patients has been validated in several rigorously performed, randomized clinical trials. Recent studies using newer generation devices have demonstrated the noninferiority of TAVR as compared with surgical aortic valve replacement in low-risk patients, supporting the increased utilization and expansion of TAVR. The use of TAVR in low-risk patients has important implications and requires a multifaceted approach that includes a highly functional multidisciplinary heart team for careful patient selection; a need to understand and help mitigate certain key complications, such as stroke, paravalvular regurgitation, and conduction disturbances; careful data collection for continual outcome assessment and improvement; and the necessary expertize and procedural volume to maintain excellent outcomes and ensure optimal clinical care pathways | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Edris, Ahmad |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Anatolian journal of cardiology |d 2014 |g 23(2020), 1 vom: 01. Jan., Seite 2-9 |w (DE-627)NLM239682068 |x 2149-2271 |7 nnns |
773 | 1 | 8 | |g volume:23 |g year:2020 |g number:1 |g day:01 |g month:01 |g pages:2-9 |
856 | 4 | 0 | |u http://dx.doi.org/10.14744/AnatolJCardiol.2019.39293 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 23 |j 2020 |e 1 |b 01 |c 01 |h 2-9 |